
<!doctype html>
<html>
  <head>
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0, user-scalable=0">
    <title>Crimean-Congo Hemorrhagic Fever virus</title>
    <link rel="stylesheet" type="text/css" href="../css/style.css">
    <link rel="stylesheet" href="../css/ir_black.css">
    <script type="text/javascript" src="../js/slideshow.js"></script>
    <script src="../js/highlight.pack.js"></script>
    <script src="../js/d3.v3.min.js"></script>
    <script>hljs.initHighlightingOnLoad();</script>
  </head>
  <body>
    <div class="progress">
      <div class="progress-bar"></div>
    </div>

    <div class="slide">
      <section>
        <h1>Crimean-Congo Hemorrhagic Fever Virus</h1>
        <h2>&nbsp;</h2>
        <h2>Christopher Wetherill</h2>
        <h2>TBMH 5054</h2>
      </section>
    </div>

    <div class="slide hidden">
      <section>
        <h3>Crimean-Congo Hemorrhagic Fever Virus</h3>
        <ul>
          <li>Tick-borne virus
            <ul>
              <li>Typically transmitted by ticks of the Hyalomma genus</li>
              <li>Has been isolated from at least 31 different species (although most are not competent vectors)</li>
            </ul>
          </li>
          <li>Three-stranded negative-sense ssRNA virus</li>
          <li>Seven distinct genotypes have been identified</li>
          <li>Estimated to have evolved around 3500 years ago based on Bayesian coalescent analysis of viral gene segments</li>
          <li>First likely report of CCHFV comes from 12th century account in modern-day Tajikistan</li>
        </ul>
      </section>
    </div>

    <div class="slide hidden">
      <section>
        <h3>Epidemiology</h3>
        <br />
        <img src="./assets/cchfv_epidemiology.png" />
        <br />
        <span class="cite">doi: 10.1016/j.antiviral.2013.07.006</span>
      </section>
    </div>

    <div class="slide hidden">
      <section>
        <h3>Epidemiology</h3>
        <br />
        <img src="./assets/tick_habitat.png" />
        <br />
        <span class="cite">doi: 10.1016/j.antiviral.2013.02.007</span>
      </section>
    </div>

    <div class="slide hidden">
      <section>
        <h3>Epidemiology</h3>
        <br />
        <img src="./assets/europe_incidence.png" />
        <br />
        <span class="cite">doi: 10.1016/j.antiviral.2013.02.007</span>
      </section>
    </div>

    <div class="slide hidden">
      <section>
        <h3>Clinical Presentation</h3>
        <span style="height: 100%; width:50%; float: left;">
          <img style="margin-top: 25%;" src="./assets/presentation.jpg" />
        </span>
        <span style="width:50%; float: right;">
          <ul>
            <li>1&ndash;3 day incubation period following tick bite</li>
            <li>Flu-like symptoms (generally resolve within 7 days)</li>
            <li>Signs of hemmorhage appear within first week</li>
            <li>Petechiae (purple spots on skin)</li>
            <li>Swollen, painful liver</li>
            <li>Death in about 30% of cases; resolution after 10 days in the remainder</li>
          </ul>
        </span>
      </section>
    </div>

    <div class="slide hidden">
      <section>
        <h3>Diagnosis</h3>
        <ul>
          <li>ELISA, RT-PCS, virus isolation, antibody detection</li>
          <li>With compatible clinical history, infection can be diagnoses during acute phase</li>
          <li>Following viral resolution, circulating antibodies against pathogen can be detected</li>
        </ul>
      </section>
    </div>

    <div class="slide hidden">
      <section>
        <h3>Life Cycle & Replication</h3>
        <ul>
          <li>It's a black box! Isn't that fun?</li>
          <li>Some evidence to suggest clathrin-, pH-, cholesterol- and microtubuls-dependent steps</li>
          <li>Maybe because it has low incidence/prevalence (~1000 new cases/year) and requires a BSL-4 lab to study?</li>
        </ul>
      </section>
    </div>

    <div class="slide hidden">
      <section>
        <h3>Host Immune Responses</h3>
        <ul>
          <li>Although geographically widespread, little is known about CCHFV's pathogenesis</li>
          <li>One theory is that virus interacts with endothelial cells directly</li>
          <li>Alternately, may interact with endothelial cells indirectly through immune cells, promoting release of soluble mediators</li>
          <li>Some evidence of innate immunosuppression by the virus and delay of adaptive response</li>
        </ul>
      </section>
    </div>

    <div class="slide hidden">
      <section>
        <h3>Host Immune Responses</h3>
        <br />
        <img src="./assets/severity.png" />
        <br />
        <span class="cite">doi: 10.1089/vbz.2012.1061</span>
      </section>
    </div>

    <div class="slide hidden">
      <section>
        <h3>Host Immune Responses</h3>
        <br />
        <img src="./assets/pathogenesis.png" />
        <br />
        <span class="cite">doi: 10.1089/vbz.2012.1061</span>
      </section>
    </div>

    <div class="slide hidden">
      <section>
        <h3>Current Therapies</h3>
        <ul>
          <li>No preventative treatments exist</li>
          <li>Current standard of care is primarily supportive management
            <ul>
              <li>Daily monitoring of complete blood count, serum electrolyte levels, coagulation indices</li>
              <li>Hydration</li>
              <li>Replacement of blood products as necessary with, e.g., fresh frozen plasma, erythrocyte, platelet solutions</li>
            </ul>
          </li>
          <li>Avoid anti-coagulants</li>
          <li>Administration of Ribavirin (typical Hep C treatment)
            <ul>
              <li>Seems to inhibit viral growth</li>
              <li>May offer survival benefit (no RCTs have been conducted...)</li>
            </ul>
          </li>
        </ul>
      </section>
    </div>

    <div class="slide hidden">
      <section>
        <h3>Prospects for Drug Development</h3>
        <ul>
          <li>Attempts to develop CCHF vaccines date back to 1960s</li>
          <li>Inactivated vaccine approved in 1970
            <ul>
              <li>Neutralizing antibodies developed within 1 month</li>
              <li>Titers decreased within 6 months</li>
              <li>No efficacy data were ever published</li>
            </ul>
          </li>
          <li>Potential for DNA vaccine encoding CCHF genome M segment</li>
        </ul>
      </section>
    </div>

    <div class="slide hidden">
      <section>
        <h3>References</h3>

        <span class="refs">Akinci, E., Bodur, H., & Leblebicioglu, H. (2013). Pathogenesis of Crimean-Congo hemorrhagic fever. <em>Vector-Borne and Zoonotic Diseases, 13</em>, 429 - 437. doi: 10.1089/vbz.2012.1061</span>

        <span class="refs"> Bente, D., Forrester, N., Watts, D., McAuley, A., Whitehouse, C., & Bray, M. (2013). Crimean-Congo hemorrhagic fever: History, epidemiology, pathogenesis, clinical syndrome and genetic diversity. <em>Antiviral Research, 100</em>, 159 - 189. doi: 10.1016/j.antiviral.2013.07.006</span>

        <span class="refs">Keshtkar-Jahromi, M., Kuhn, J., Christova, I., Bradfute, S., Jahrling, P., & Bavari, S. (2011). Crimean-Congo hemorrhagic fever: Current and future prospects of vaccines and therapies. <em>Antiviral Research, 90</em>, 85 - 92. doi: 10.1016/j.antiviral.2011.02.010</span>

        <span class="refs">Mardani, M., Rahnavardi, M., & Sharifi-Mood, B. (2010). Current treatment of Crimean-Congo hemorrhagic fever in children. <em>Expert Review of Anti-Infective Therapy, 8</em>, 911 - 918. doi: 10.1586/eri.10.67</span>

        <span class="refs">Mertens, M., Schmidt, K., Ozkul, A., & Froschup, M. (2013). The impact of Crimean-Congo hemorrhagic fever virus on public health. <em>Antiviral Research, 98</em>, 248 - 260. doi: 10.1016/j.antiviral.2013.02.007</span>

        <span class="refs">Simon, M., Johansson, C., & Mirazimi, A. (2009a). Crimean-Congo hemorrhagic fever virus entry and replication is clathrin-, pH- and cholesterol dependent. <em>Journal of General Virology, 90</em>, 210 - 215. doi: 10.1099/vir.0.006387-0</span>

        <span class="refs">Simon, M., Johansson, C., & Mirazimi, A. (2009b). Microtubule-dependent and microtubule-independent steps in Crimean-Congo hemorrhagic fever virus replication cycle. <em>Virology, 385</em>, 313 - 322. doi: 10.1016/j.virol.2008.11.020</span>
      </section>
    </div>

    <script>
      var data = [];
      var slideLen = document.getElementsByClassName('slide').length;
      for(i = 1; i <= slideLen; i++) {
      	data.push(i);
      }

      d3.selectAll("div.slide")
        .data(data)
        .attr("id", function(d) { return "slide-" + d; });

      d3.selectAll("section").attr("class", "slide-content");
    </script>

    <div class="controls">
      <div class="arrow prev"></div>
      <div class="arrow next"></div>
    </div>
  </body>
</html>